For research use only. Not for use in humans.

Imalumab (Anti-MIF)

Synonyms: GIF, GLIF

Imalumab (Anti-MIF) is a human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory, and antineoplastic activities. MW: 145.5 kD.

Imalumab (Anti-MIF)

Quality Control

Batch: A240001 Purity: 99% Protein concentration: 7.38mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation MIF
BTZO-1 0
ISO-1 18
4-IPP 3
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Imalumab (Anti-MIF) is a human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory, and antineoplastic activities. MW: 145.5 kD.

Product Details

CAS No. 1430205-07-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01765790 COMPLETED Metastatic Adenocarcinoma of the Colon or Rectum; Malignant Solid Tumors Baxalta now part of Shire 2012-06-14 PHASE1
NCT01541670 TERMINATED Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Systemic Lupus Erythematosus Baxalta now part of Shire 2011-11-28 PHASE1

(data from https://clinicaltrials.gov, updated on 2021-05-05)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.